Otsuka Holdings Co., Ltd.: Carcinoma, Non-Small-Cell Lung trials

The registry lists 10 Carcinoma, Non-Small-Cell Lung studies with Otsuka Holdings Co., Ltd. as lead sponsor. 3 are open to participants now and 2 have results posted.

Phase 1 5Phase 2 3Phase 3 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An EAP Treatment Protocol of ZipalertinibAvailableNCT07601399
• A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionRecruitingNCT07128199Phase 3
• AB122 Platform StudyRecruitingNCT04999761Phase 1
• A Study of TAS3351 in NSCLC Patients With EGFRmtTerminatedNCT05765734Phase 1Results posted
• A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1CompletedNCT02855125Phase 2Results posted
• REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)Active, not recruitingNCT05973773Phase 3
• A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor CancerTerminatedNCT04982926Phase 1
• Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant CancerTerminatedNCT04965818Phase 1
• A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With CrizotinibCompletedNCT01712217Phase 1/2
• Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung CancerCompletedNCT00652561Phase 2